Latest Conference Articles

Women with DCIS treated with radiation therapy had no increased risk of cardiovascular disease compared with women in the general population or women with DCIS treated with surgery.

Patients with DCIS who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence.

Naomi B. Boekel, MSc, discusses the results from a large study that showed that radiation therapy for DCIS does not seem to increase cardiovascular disease risk.

Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.

The American Society of Clinical Oncology (ASCO) 2013 Annual Meeting was held in Chicago, Illinois, from May 31 to June 4, 2013. Here's our slideshow from the conference.

An updated blog from the 2013 ASCO Annual Meeting held in Chicago.

An updated blog from the 2013 ASCO Annual Meeting held in Chicago.

At the press briefing on Monday, ASCO featured advances in lung and breast cancer treatment and prevention and new insight on the nation’s cancer drug shortages.

An updated blog from the 2013 ASCO Annual Meeting held in Chicago.

On Sunday, ASCO released data from five pivotal studies on reducing cervical cancer deaths worldwide, first therapies for two rare cancers, and treatment advances for breast and brain cancers.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

An updated blog from the 2013 ASCO Annual Meeting held in Chicago.

In a press briefing on Saturday, ASCO highlighted important advances in treatment for multiple aggressive cancers, and new insight on HPV related cancer risk.

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses targeting the phosphoinositide 3-kinase (PI3K) in breast cancer.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the challenges of triple-negative breast cancer.

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Villejuif, France, discusses the need for new testing methods.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses genomic testing in breast cancer.

The 30th Annual Miami Breast Cancer Conference (MBCC) at the Fontainebleau Miami Beach Hotel, in Miami Florida, from March 7-10, 2013.

Approximately 20% of human breast cancers are characterized by overexpression of the HER2 receptor tyrosine kinase molecule. Multiple anitbodies have been designed to specifically target HER2, and each is able to target the molecule at a different epitope.

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses drug toxicity among targeted agents.

So far, there are no conclusive biomarkers to help identify subsets of patients who would benefit from antiangiogenic therapies, creating a barrier to the use of such treatments, Rugo said in her MBCC abstract.

Patients with ER-positive breast cancer, which accounts for approximately 70% of all cases, have benefited from the use of hormonal therapies to treat their disease.

Although targeted antibodies in cancer have been promising, most have only marginal activity in their targeted cancer and must be paired with a chemotherapeutic agent to maximize efficacy.

Gene expression profiling via the Oncotype DX 21-gene recurrence score assay has been used to assess risk and predict recurrence in hundreds of thousands of women over the course of nearly a decade.

The development of new drug combinations to treat patients with ER-negative breast cancer is being advanced by a growing understanding of the protein kinase activity along the EGFR pathway.

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the use of the reverse phase protein microarray (RPPA).

Fabrice André, MD, PhD, has focused his research on translational oncology and the development of novel targeted agents for the treatment of breast cancer through his research as director of INSERM Unit U981 at the Institut Gustave-Roussy in Villejuif, France.

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the Miami Breast Cancer Conference.

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, discusses the use of pomalidomide in relapsed or refractory multiple myeloma.